An Alternative Approach for Anti-Alzheimer’s Compounds from Plant Extracts

Pratap, G.; Shantaram, Manjula

doi:10.1201/9780429318429-2

Cited by 2 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plant leaves extractwas then subjected to a screening of different phytochemicals as flavonoids, saponins, tri-terpenoids, alkaloids, phenolic compounds, reducing sugars, steroids, proteins, carbohydrates, etc. Using the procedure reported previously ( Pratap and Shantaram, 2020a ).…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, products made from plants are less expensive and have fewer adverse effects ( Bhandary et al, 1995 ; Harsha et al, 2003 ) In this perspective, many phytochemicals from medicinal plants are investigated for anti-cholinesterases or anti-AChE activity and the most popular field of research in the management of AD as the prevalence of AD has increased ( Adewusi & Steenkamp, 2011 ; Chapter 5 Purification and Characterisation, n.d. ; Luccarini et al, 2015 ). Ethno-medicinal plants such as Bacopa monera , Mentha longifolia L.), Ocimum basilicum L., and others are used to treat neurological illnesses including AD recently ( Pratap et al, 2017 ; Pratap & Shantaram, 2020a ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro evaluation of the neuroprotective potential of Olea dioica against Aβ peptide-induced toxicity in human neuroblastoma SH-SY5Y cells

Kenchappa,

Karthik,

Vijendra

et al. 2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a type of neurodegenerative disease, associated with the hastening of ROS, acetylcholinesterase (AChE) activity, and amyloid β peptides plaques in the brain. The limitations and side effects of existing synthetic drugs incline toward natural sources. In the present communication active principles of methanolic extract of Olea dioica Roxb, leaves are explored as an antioxidant, AChE inhibitor, and anti-amyloidogenic. Furthermore, neuroprotection against the amyloid beta-peptide has been studied. The bioactive principles were identified by GC-MS and LC-MS and further subjected to antioxidant (DPPH and FRAP) and neuroprotection (AChE inhibition, ThT binding, and MTT assay, DCFH-DA and lipid peroxidation (LPO) assay using neuroblastoma (SHSY-5Y) cell lines) assays. Methanolic extract of O. dioica Roxb, leaves was found to contain polyphenols and flavonoids. In vitro assays exhibited potential antioxidant and anti-AChE (˃50%) activities. ThT binding assay indicated protection against amyloid-beta aggregation. MTT assay, Aβ1-40 (10 µM) with extract increase the cell viability (˃50%) and showed significant cytotoxicity to SHSY-5Y cells. ROS level (˃25%) significantly decreased in the Aβ1-40 (10 µM) + extract (15 and 20 μM/mL) and LPO assay (˃50%) suggesting prevention of cell damage. Results advocate that O. dioica leaves are a good source of antioxidants, anti-AChE, and anti-amyloidogenic compounds which may be further evaluated as a natural medicine for the treatment of AD.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

In vitro evaluation of the neuroprotective potential of Olea dioica against Aβ peptide-induced toxicity in human neuroblastoma SH-SY5Y cells

Kenchappa,

Karthik,

Vijendra

et al. 2023

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a result, alternate sources of PDE inhibitors are required to eliminate or decrease the side effects of synthetic PDE inhibitors ( Anand Ganapathy et al, 2021 ). Natural or traditional herbs are considered as most desirable alternative sources for the development of new active pharmacophores since they have demonstrated bioactivities with potential utility for health improvement as well as less side effects than synthetic medications ( Pratap et al, 2017 ; Pratap and Shantaram, 2020 ).…”

Section: Phosphodiesterases and Their Inhibitorsmentioning

confidence: 99%

“…However, the synthetic PDE inhibitors adverse effects have limited their usage in clinical practice. Natural products ingredients are widely accepted and regarded harmless ( Pratap and Shantaram, 2020 ; Pratap et al, 2021 ). Several plant derived components have been investigated pre-clinically for PDE inhibitory action throughout the last decade ( Temkitthawon et al, 2011 ), and they were proved to be as effective as synthetic drugs in inhibiting PDEs ( Figure 4 ).…”

Section: Phytochemicals For the Inhibition Of Phosphodiesterasesmentioning

confidence: 99%

“…Although some therapeutic medications failed at various phases of clinical testing, the increase of remedial approaches for mitigating AD progression has been encouraging ( Pratap and Shantaram, 2020 ). The majority of these therapeutic medications inhibit only one of the numerous pathways involved in AD, which explains their lack of efficacy ( Wen et al, 2015 ).…”

Section: Phytochemicals For the Inhibition Of Phosphodiesterasesmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease

Sheng¹,

Zhang²,

Wu³

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia and is ranked as the 6th leading cause of death in the US. The prevalence of AD and dementia is steadily increasing and expected cases in USA is 14.8 million by 2050. Neuroinflammation and gradual neurodegeneration occurs in Alzheimer’s disease. However, existing medications has limitation to completely abolish, delay, or prevent disease progression. Phosphodiesterases (PDEs) are large family of enzymes to hydrolyze the 3’-phosphodiester links in cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in signal-transduction pathways for generation of 5’-cyclic nucleotides. It plays vital role to orchestrate several pharmacological activities for proper cell functioning and regulating the levels of cAMP and cGMP. Several evidence has suggested that abnormal cAMP signaling is linked to cognitive problems in neurodegenerative disorders like AD. Therefore, the PDE family has become a widely accepted and multipotential therapeutic target for neurodegenerative diseases. Notably, modulation of cAMP/cGMP by phytonutrients has a huge potential for the management of AD. Natural compounds have been known to inhibit phosphodiesterase by targeting key enzymes of cGMP synthesis pathway, however, the mechanism of action and their therapeutic efficacy has not been explored extensively. Currently, few PDE inhibitors such as Vinpocetine and Nicergoline have been used for treatment of central nervous system (CNS) disorders. Considering the role of flavonoids to inhibit PDE, this review discussed the therapeutic potential of natural compounds with PDE inhibitory activity for the treatment of AD and related dementia.

show abstract

An Alternative Approach for Anti-Alzheimer’s Compounds from Plant Extracts

Cited by 2 publications

References 1 publication

In vitro evaluation of the neuroprotective potential of Olea dioica against Aβ peptide-induced toxicity in human neuroblastoma SH-SY5Y cells

In vitro evaluation of the neuroprotective potential of Olea dioica against Aβ peptide-induced toxicity in human neuroblastoma SH-SY5Y cells

Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease

Contact Info

Product

Resources

About